Parkinson Disease
Parkinson Disease - Related Videos
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
0 Views •
Cited by 1 •
2007
Ole Isacson gives a concise overview of Parkinsons's disease, its causes, therapeutic strategies, and advances in Parkinson's research.
01:24
Parkinson's Disease: Treatment
0 Views •
2024
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury. Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24
Parkinson Disease ll: Pathophysiology
0 Views •
2026
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
06:07
Histological Examination of Mitochondrial Morphology in a Parkinson's Disease Model
0 Views •
Cited by 3 •
2023
This study presents a method to analyze the morphology of mitochondria based on immunostaining and image analysis in mouse brain tissue in situ. It also describes how this allows one to detect changes in mitochondrial morphology induced by protein aggregation in Parkinson's disease models.
08:06
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
0 Views •
Cited by 57 •
2010
Parkinson disease is caused by loss of dopaminergic innervation to the striatum, which can be experimentally induced by 6-OH-dopamine. We describe how to perform a stereotaxic lesion and to monitor apomorphine-induced rotational behavior in mice. This model is useful and reliable for testing new therapies for Parkinson disease.
FAQs
Loss of dopamine-producing neurons changes signaling within basal ganglia circuits, which are involved in organizing movement. This disruption helps explain why motor function becomes a central focus of Parkinson disease research. Studying these circuit-level effects connects cellular degeneration with changes in nervous-system organization and helps researchers evaluate treatments intended to relieve movement-related symptoms.
Abnormal accumulation of alpha-synuclein may contribute to neuronal dysfunction and degeneration. Its involvement gives researchers a molecular process to investigate alongside dopamine loss, rather than viewing the disease only as a circuit disorder. Research on alpha-synuclein can therefore help clarify how protein-related cellular changes participate in progression and may inform biomarker or treatment development.
Several interacting factors are examined, including genetic influences, cellular stress, protein processing, and neuroinflammation. These areas represent different levels of biology, from inherited or molecular contributors to broader cellular responses. Comparing them helps researchers investigate why neuronal damage progresses and how multiple mechanisms might be connected within the disease process.
Animal and cell models provide experimental systems for examining mechanisms linked to neuronal damage, including genetic factors, cellular stress, protein processing, and neuroinflammation. They also support the investigation of potential biomarkers and treatments before researchers assess their broader relevance. Together, these models connect biological observations with efforts to understand progression and therapeutic possibilities.
Biomarkers are studied as measurable indicators that may help researchers investigate disease-related biology and progression. In Parkinson disease research, they are developed alongside animal and cell models and treatment studies. Their value lies in supporting the detection or tracking of relevant changes, although the overview does not specify particular biomarkers or establish a single validated marker.
Treatment research has two distinct goals: relieving symptoms and slowing neuronal damage. This distinction matters because improving movement-related symptoms does not necessarily demonstrate that degeneration has been reduced. Biological studies therefore examine treatments in relation to dopamine signaling, cellular damage, and disease progression, while also using models and biomarkers to support therapeutic development.